biologic

Novolin 70/30

insulin isophane human and insulin human

Loss of exclusivityJune 2003projected — 12-year biologic exclusivity estimate
CompanyNovo Nordisk Inc.

Drug detail

Brand nameNovolin 70/30
Active ingredientinsulin isophane human and insulin human
Strength300UNITS/10ML (30UNITS/ML); 700UNITS/10ML (70UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 1991
Marketing statusOTC

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Novolin 70/30 patent cliff — loss of exclusivity June 2003 | CliffBio